Контакты | НИАРМЕДИК ПЛЮС

     
 

Media



Non-interventional Trial of Kagocel Enters the International Register of Clinical Trials ClinicalTrials.gov


2016-12-12 13:41

In November 2016, NEARMEDIC completed the international post-authorization study "Treatment of SARS and influenza in routine clinical practice (Treatment of Influenza in Routine Clinical Practice — FLU-EE)", which made it possible to obtain a unique scope of new data on the treatment of these diseases. The study involved 262 medical centers from Russia, Moldova, Armenia and Georgia, and 18,946 patients from 18 to 93 years of age with proven cases of SARS or influenza. The team of researchers included primary care specialists, physicians, family doctors and general practitioners. The results and description of the non-intervention trial have been made public by NEARMEDIC on the web at ClinicalTrials.gov

 

The website ClinicalTrials.gov created by the National Institutes of Health (NIH) together with the US Food and Drug Administration (US FDA) is the international source of public information on development of drugs, medical devices and procedures, and on the study  of their efficacy, safety of drugs and medical devices, organized with the participation of both public and private funding. The ClinicalTrials.gov website contains data on more than 200,000 trials conducted in 194 countries.

 

This resource is designed to serve anyone willing to obtain information about drug trial procedures, as well as such additional information as the inclusion criteria, socio-demographic data of the study population, the criteria for the safety assessment of a drug, research centers, etc.

 

By publishing information about the non-intervention trial "Treatment of SARS and influenza in routine clinical practice (Treatment of Influenza in Routine Clinical Practice — FLU-EE)", NEARMEDIC makes it available to the international community. It includes not professionals in medical and pharmaceutical fields alone, but also patient organizations, regulatory institutions, as well as patients and their families. Data is open for anyone interested.

 

Today, the drug research database on the ClinicalTrials.gov website contains complete information about the design of the research conducted by NEARMEDIC, the description of the patient population, and parameters for assessing the efficacy and safety of antiviral therapy (including that with the use of Kagocel).

 

 

Reference:

 

ClinicalTrials.gov is an international registry of clinical trials and observational studies and programs. Publication of protocol descriptions (and in some cases, results) of the studies makes this information publicly available to patients, their families, health care professionals, academia and the public. The website was launched in 2000 by the National Institutes of Health (NIH) in partnership with the US Food and Drug Administration (US FDA).

 

Kagocel is an original antiviral drug developed by Russian scientists for the treatment and prevention of influenza and SARS for adults and children from the age of three. The drug is available without prescription, it has a high safety profile and a convenient dosage regimen.

Tags: